Perioperative Treatment in EGFR ‐Mutant Early‐Stage Non‐Small Cell Lung Cancer: Current Evidence and Future Perspectives
Thoracic Cancer · 2025
DOI: 10.1111/1759-7714.70018 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Xiaobei Guo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medi…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation, Perioperative Care. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Adjuvant osimertinib administered over a 3‐year period in patients diagnosed with stage IB–IIIA non‐small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutations has not only shown improvement in event‐free survival but also demonstrated a prolonged overall survival (OS), leading to its approval as a standard treatment in this context. Meanwhile, no targeted studies have been conducted on the efficacy of adjuvant immune checkpoint inhibitors in these patients. Although studies such as IMPOWER‐010 and KEYNOTE‐091 have included a small number of patients with positive driver genes, no definitive conclusions regarding the OS benefit have been established. Neoadjuvant targeted therapy is not currently recommended because of insufficient evidence, characterized by a low depth of pathological response and no reported improvement in survival outcomes. The same is true for neoadjuvant immunotherapy in patients with EGFR mutations. Although numerous issues such as refining patient population selection, determining appropriate combination therapy regimens, establishing primary endpoints, assessing the influence of perioperative complications, and accurately evaluating the clinical application of circulating tumor DNA in various scenarios exist, several promising ongoing trials, including ADAURA2 and NEOADURA, are expected to provide valuable insights that will help address these questions. Here, we summarize the available evidence and clinical issues that need to be considered to optimize clinical decision‐making for patients with EGFR‐mutant NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Thoracic Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, China.
- Department of Surgical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
- Department of Respiratory and Critical Care Medicine, Shengli Clinical Medical College, Fujian Medical University, Fujian Provincial Hospital, Fuzhou, China.
ORCID-Profile: Xiaobei Guo, Chao Guo, Jian Zhou, Yan Xu
Förderung
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Guo, X., Liu, X., Guo, C., Miao, Q., Cheng, X., Hong, X., Li, H., Qiu, X., Xiang, Y., Zheng, D., Zhou, J., Jiang, L., Xu, Y., & Wang, M. (2025). Perioperative Treatment in EGFR ‐Mutant Early‐Stage Non‐Small Cell Lung Cancer: Current Evidence and Future Perspectives. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70018
Vancouver
Guo X, Liu X, Guo C, Miao Q, Cheng X, Hong X, et al. Perioperative Treatment in EGFR ‐Mutant Early‐Stage Non‐Small Cell Lung Cancer: Current Evidence and Future Perspectives. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70018
BibTeX
@article{Guo2025,
author = {Guo, Xiaobei and Liu, Xiaoyan and Guo, Chao and Miao, Qian and Cheng, Xinghua and Hong, Xuan and Li, Hongru and Qiu, Xiaoming and Xiang, Yi and Zheng, Di and Zhou, Jian and Jiang, Liyan and Xu, Yan and Wang, Mengzhao},
title = {Perioperative Treatment in EGFR ‐Mutant Early‐Stage Non‐Small Cell Lung Cancer: Current Evidence and Future Perspectives},
journal = {Thoracic Cancer},
year = {2025},
doi = {10.1111/1759-7714.70018}
}
EUVIMED